Company / Operating Cash Flow
Amylyx Pharmaceuticals, Inc. Operating Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$123.3M
FY2025
5-year range
-$179.9M / $11.9M
FY2021-FY2025
Trend
+26.4%
vs FY2024
Sector context
#134 of 216
Health Care
What the data says
At -$123M, Amylyx Pharmaceuticals, Inc.'s operating cash flow ranks #134 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 5 years, ranging from -$180M in FY2022 to $12M in FY2023.
Based on SEC 10-K filings.
-$123M in FY2025.
Declined from $12M to -$123M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#134 of 216 in Health CareTop 62% of 216This company -$123.3M Sector average $658.7M
▼
-118.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 26.4% year-over-year.
- Ranks #134 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$123.3M | +26.4% |
| FY2024 | -$167.6M | -1506.6% |
| FY2023 | $11.9M | +106.6% |
| FY2022 | -$179.9M | -140.5% |
| FY2021 | -$74.8M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026